1. Signaling Pathways
  2. GPCR/G Protein
  3. CXCR
  4. CXCR2 Isoform



CXCR2 Related Products (24):

Cat. No. Product Name Effect Purity
  • HY-16711
    Antagonist 99.87%
    SB225002, a potent, selective and non-peptide CXCR2 antagonist, inhibits 125I-IL-8 binding to CXCR2 with an IC50 of 22 nM.
  • HY-13848
    AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human CX3CR1 receptor; antagonizes CX3CR1 and CXCR2 with Kis of 3.9 and 2800 nM, respectively.
  • HY-15251
    Inhibitor 99.98%
    Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC50s of 1 and 100 nM, respectively.
  • HY-10198
    Antagonist 99.13%
    Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both CXCR1 and CXCR2, with Kd values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly.
  • HY-19855
    Antagonist 99.63%
    AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.
  • HY-147392
    CXCR2 antagonist 8
    CXCR2 antagonist 8 is a potent and selective CXCR2 antagonist.
  • HY-144780
    CXCR2 antagonist 4
    CXCR2 antagonist 4 (compound 7) is a potent CXCR2 antagonist with an IC50 value of 0.13 μM.
  • HY-119339
    Inhibitor 98.64%
    SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2.
  • HY-15252
    Reparixin L-lysine salt
    Inhibitor 99.93%
    Reparixin L-lysine salt is a potent and specific allosteric inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR1-mediated chemotaxis (IC50=1 nM).
  • HY-19768
    Antagonist 98.45%
    Danirixin is a selective, and reversible CXCR2 antagonist, with IC50 of 12.5 nM for CXCL8.
  • HY-101022
    Inhibitor 99.47%
    CXCR2-IN-1 is a central nervous system penetrant CXCR2 antagonist with a pIC50 of 9.3.
  • HY-50688
    Antagonist ≥99.0%
    SB-265610 is a selective, competitive, nonpeptide and allosteric CXCR2 antagonist.
  • HY-101407
    Nicotinamide N-oxide
    Antagonist 99.85%
    Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the CXCR2 receptor.
  • HY-120878
    Antagonist 98.45%
    CXCR2-IN-2 is a selective, brain penetrant, and orally bioavailable CXCR2 antagonist (IC50=5.2 nM/1 nM in β-arrestin assay/CXCR2 Tango assay, respectively).
  • HY-13021
    Antagonist 99.32%
    SRT3190 is an antagonist of CXCR2, used in the research of chemokine mediated diseases.
  • HY-18263C
    Elubrixin tosylate
    Antagonist 99.74%
    Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.
  • HY-19519A
    Ladarixin sodium
    Antagonist 99.15%
    Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist.
  • HY-10011
    SCH 563705
    Antagonist 98.20%
    SCH 563705 is a potent and orally available CXCR2 and CXCR1 antagonist, with IC50s of 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively.
  • HY-15462
    Antagonist 99.82%
    SRT3109 is an antagonist of CXCR2, with a pIC50 of 8.2, and used in the research of chemokine mediated diseases.
  • HY-18263A
    Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.